Yale spinout 3PrimiR pulls in $2M in funding

Spawned by Yale University, biotech company 3PrimiR Inc., which is focused on applying microRNA discoveries to cancer diagnostics, has raised $2 million in a planned $4 million equity financing, according to federal documents.

According to the website of Yale’s Office of Cooperative Research, Westport, Conn.-based 3PrimiR was founded by Yale scientists based on their discoveries of the predictive roles of mutations affecting microRNA in cancers. The filing with the U.S. Securities and Exchange Commission notes the two company executives as Barbara Mignogna-Korus and Andrew Weidhaas.  (read more)

Incoming search terms for this article:

• 3primiR
• barbara mignogna korus
• 3PrimiR Inc
• andrew weidhaas
• yale mirna company
• research on RNA biomarkers at yale
• berchuk weidhaas
• barbra mignogna-korus
• Barbara Mognogna Korus
• barbara mignogna-korus

Related posts:

1. Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University
2. Tiny genetic variation can predict ovarian cancer outcome
3. ARRA Funding Supports microRNA Research
4. Targeting a Master Regulator of Disease
5. Largest microRNA Therapeutics Alliance To Date

Tagged as: discovery, microrna, News, Yale